Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines (review)

International Journal of Oncology

Volumn 12, Issue 2, 1998, Pages 273-286

  Sharif, Mohammed ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bombesin; Brain tumor; Mitogenic signaling; Neuropeptide receptors; Substance P

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; BOMBESIN RECEPTOR; MIDOSTAURIN; NEUROPEPTIDE RECEPTOR; RAPAMYCIN; SUBSTANCE P; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CALCIUM MOBILIZATION; GLIOBLASTOMA; HUMAN; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ADULT; ASTROCYTOMA; BOMBESIN; BRAIN NEOPLASMS; CELL DIVISION; CHILD; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MITOGENS; RECEPTORS, NEUROPEPTIDE; SIGNAL TRANSDUCTION; SIROLIMUS; SUBSTANCE P; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031908007     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 21: 126-138, 1994.
2. Kleihues P, Burger PC and Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3: 255-268, 1993.
3. Kramer ED and Packer RJ: Chemotherapy of malignant brain tumors in children. Clin Neuropharmacol 15: 163-185, 1992.
4. Cohen ME and Duffner PK: Brain Tumors in Children: Principles of Diagnosis and Treatment. Raven Press, Ltd., New York, pp1-11, 1994.
5. Brown MT, Friedman HS, Oakes WJ, Boyko OB, Hockenberger B and Schold SC Jr: Chemotherapy for pilocytic astrocytomas. Cancer 71: 3165-3172, 1993.
6. Luo W, Sharif TR and Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983-4991, 1996.
7. Sharif TR, Luo W, Houghton PJ and Sharif M: Substance K peptide induces mitogenesis by activating the mitogen-activated protein kinase signaling pathway through the substance P receptor (NK-1 subtype) in human astrocytoma cells. Cell Pharmacol 3: 441-449, 1996.
8. Sharif TR, Luo W and Sharif M: Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol 130: 119-130, 1997.
9. Sharif M, Sasakawa N and Hanley MR: Malignant transformation by G-protein-coupled hormone receptors. Mol Cell Endocrinol 100: 115-119, 1994.
10. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
11. Privalsky ML: v-erbA, nuclear hormone receptors, and oncogenesis. Biochim Biophys Acta 1114: 51-62, 1992.
12. Privalsky ML: Retinoid and thyroid hormone receptors: ligand-regulated transcription factors as proto-oncogenes. Semin Cell Biol 3: 99-106, 1992.
13. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
14. Probst WC, Snyder LA, Schuster DI, Brosius J and Sealfon SC: Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 11: 1-20, 1992.
15. Dohlman HG, Thorner J, Caron MG and Lefkowitz RJ: Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60: 653-688, 1991.
16. Humphrey PA, Gangarosa LM, Wong AJ, Archer GE, Lund-Johansen M, Bjerkvig R, Laerum OD, Friedman HS and Bigner DD: Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 178: 1413-1420, 1991.
17. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD and Bigner SH: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48: 2231-2238, 1988.
18. Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B and Bigner DD: Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet 29: 165-170, 1987.
19. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS and Bigner DD: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-8022, 1990.
20. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991.
21. Fuller GN and Bigner SH: Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 276: 299-306, 1992.
22. Wong AJ, Zoltick PW and Moscatello DK: The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol 21: 139-148, 1994.
23. Yamaguchi F, Saya H, Bruner JM and Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484-488, 1994.
24. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA and Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553, 1992.
25. Hennig IM, Laissue JA, Horisberger U and Reubi JC: Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61: 786-792, 1995.
26. Ziehe M, Morbidelli L, Pacini M, Geppetti P, Alessandri G and Maggi CA: Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvascular Res 40: 264-278, 1990.
27. Otsuka M and Yoshioka K: Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73: 229-308, 1993.
28. Maggio JE: Tachykinins. Annu Rev Neurosci 11: 13-28, 1988.
29. Nakanishi S: Mammalian tachykinin receptors. Annu Rev Neurosci 14: 123-136, 1991.
30. S6K) in human astrocytoma cells. Int J Oncol 11: 797-805, 1997.
31. Luo W, Sharif TR, Houghton PJ and Sharif M: CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein (MAP) kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Differ 8: 1225-1240, 1997.
32. Johnson CL and Johnson CG: Characterization of receptors for substance P in human astrocytoma cells: radioligand binding and inositol phosphate formation. J Neurochem 58: 471-477, 1992.
33. Lee CM, Kum W, Cockram CS, Teoh R and Young JD: Functional substance P receptors on a human astrocytoma cell line (U-373 MG). Brain Res 488: 328-331, 1989.
34. Battey J and Wada E: Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci 14: 524-528, 1991.
35. Kroog GS, Jensen RT and Battey JF: Mammalian bombesin receptors. Med Res Rev 15: 389-417, 1995.
36. Spindel ER, Giladi E, Segerson TP and Nagalla S: Bombesinlike peptides: of ligands and receptors. Recent Prog Horm Res 48: 365-391, 1993.
37. Rozengurt E and Sinnett-Smith J: Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci USA 80: 2936-2940, 1983.
38. Spindel ER, Giladi E, Brehm P, Goodman RH and Segerson TP: Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 4: 1956-1963, 1990.
39. Corjay MH, Dobrzanski DJ, Way JM, Viallet J, Shapira H, Worland P, Sausville EA and Battey JF: Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 266: 18771-18779, 1991.
40. Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R and Battery J: cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron 6: 421-430, 1991.
41. Heslop JP, Blakeley DM, Brown KD, Irvine RF and Berridge MJ: Effects of bombesin and insulin on inositol 1,4,5)trisphosphate and inositol (1,3,4)trisphosphate formation in Swiss 3T3 cells. Cell 47: 703-709, 1986.
42. Bishop AE, Hamid QA, Adams C, Bretherton-Watt D, Jones PM, Denny P, Stamp GW, Hurt RL, Grimelius L, Harmar AJ, et al: Expression of tachykinins by ileal and lung carcinoid tumors assessed by combined in situ hybridization, immunocytochemistry, and radioimmunoassay. Cancer 63: 1129-1137, 1989.
43. Conlon JM, Deacon CF, Grimelius L, Cedermark B, Murphy RF, Thim L and Creutzfeldt W: Neuropeptide K-(1-24)-peptide: storage and release by carcinoid tumors. Peptides 9: 859-866, 1988.
44. Norheim I, Wilander E, Obcrg K, Theodorsson-Norheim E, Lundqvist ML, Lindgren P and Bergh J: Tachykinin production by carcinoid tumours in culture. Eur J Cancer Clin Oncol 23: 689-695, 1987.
45. Moody TW, Pert CB, Gazdar AF, Carney DN and Minna JD: High levels of intracellular bombesin characterize human small cell lung carcinoma. Science 214: 1246-1248, 1981.
46. Erisman MD, Linnoila RI, Hernandez O, Di Augustine RP and Lazarus LH: Human lung small cell carcinoma contains bombesin. Proc Natl Acad Sci USA 79: 2379-2383, 1982.
47. Sorenson GD, Bloom SR, Ghatei MA, Del Prete SA, Cate CC and Pettengill OS: Bombesin production by human small cell carcinoma of the lung. Regul Pept 4: 59-66, 1982.
48. Payan DG, Brewster DR and Goetzl EJ: Specific stimulation of human T lymphocytes by substance P. J Immunol 131: 1613-1615, 1983.
49. Lotz M, Carson DA and Vaughan JH: Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235: 893-895, 1987.
50. Reid TW, Murphy CJ, Iwahashi CK, Foster BA and Mannis MJ: Stimulation of epithelial cell growth by the neuropeptide substance P. J Cell Biochem 52: 476-485, 1993.
51. Nilsson J, von Euler AM and Dalsgaard CJ: Stimulation of connective tissue cell growth by substance P and substance K. Nature 315: 61-63, 1985.
52. Ziehe M, Morbidelli L, Pacini M, Dolara P and Maggi CA: NKl-receptors mediate the proliferative response of human fibroblasts to tachykinins. Br J Pharmacol 100: 11-14, 1990.
53. Torrens Y, Beaujouan JC, Saffroy M, Daguet de Montety MC, Bergstrom L and Glowinski J: Substance P receptors in primary cultures of cortical astrocytes from the mouse. Proc Natl Acad Sci USA 83: 9216-9220, 1986.
54. Torrens Y, Daguet de Montety MC, El Etr M, Beaujouan JC and Glowinski J: Tachykinin receptors of the NKI type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J Neurochem 52: 1913-1918, 1989.
55. Marriott DR, Wilkin GP and Wood JN: Substance P-induced release of prostaglandins from astrocytes: regional specialization and correlation with phosphoinositol metabolism. J Neurochem 56: 259-265, 1991.
56. Heuillet E, Menager J, Fardin V, Flamand O, Bock M, Garret C, Crespo A, Fallourd AM and Doble A: Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U-373MG. J Neurochem 60: 868-876, 1993.
57. Eistetter HR, Mills A, Brewster R, Alouani S, Rambosson C and Kawashima E: Functional characterization of neurokinin-1 receptors on human U-373MG astrocytoma cells. Glia 6: 89-95, 1992.
58. Allen JM, Hoyle NR, Yeats JC, Ghatei MA, Thomas DG and Bloom SR: Neuropeptides in neurological tumours. J Neuro-Oncol 3: 197-202, 1985.
59. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A and Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316: 823-826, 1985.
60. Carney DN, Cuttitta F, Moody TW and Minna JD: Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47: 821-825, 1987.
61. Bologna M, Festuccia C, Muzi P, Biordi L and Ciomci M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63: 1714-1720, 1989.
62. 2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993.
63. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T and Cutler GB Jr: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365: 652-654, 1993.
64. Parma J, Duprez L, van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J and Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651, 1993.
65. Clapham DE: Mutations in G-protein-linked receptors: novel insights on disease. Cell 75: 1237-1239, 1993.
66. Egan SE and Weinberg RA: The pathway to signal achievement. Nature 365: 781-783, 1993.
67. Anderson NG, Mailer JL, Tonks NK and Sturgill TW: Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343: 651-653, 1990.
68. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ and Sturgill TW: Identification of the regulatory phosphorylation sites in pp42/ mitogen-activated protein kinase (MAP kinase). EMBO J 10: 885-892, 1991.
69. Nakielny S, Cohen P, Wu J and Sturgill T: MAP kinase activator from insulin-stimulated skeletal muscle is a protein threonine/ tyrosine kinase. EMBO J 11: 2123-2129, 1992.
70. Kwatra MM, Schwinn DA, Schreurs J, Blank JL, Kim CM, Benovic JL, Krause JE, Caron MG and Lefkowitz RJ: The substance P receptor, which couples to Gq/11, is a substrate of beta-adrenergic receptor kinase 1 and 2. J Biol Chem 268: 9161-9164, 1993.
71. Couldwell WT, Weiss MH, De Giorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS and Apuzzo ML: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-489, 1993.
72. Couldwell WT, Hinton DR and Law RE: Protein kinase C and growth regulation in malignant gliomas. Neurosurgery 35: 1184-1186, 1994.
73. Goodnight J, Mischak H and Mushinski JF: Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv Cancer Res 64: 159-209, 1994.
74. Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GED, Stabel S and Mark GE: Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene 7: 2259-2262, 1992.
75. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D and Rapp UR: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364: 249-252, 1993.
76. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci 19: 474-480, 1994.
77. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W and Weinstein IB: PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 13: 2517-2526, 1996.
78. Sonenberg N: mRNA 5' cap-binding protein eIF4E and control of cell growth. In: Translational Control. Hershey JWB, Mathews MB and Sonenberg N (eds). Cold Spring Harbor Press, New York, pp245-269, 1996.
79. Brooks RF: Continuous protein synthesis is required to maintain the probability of entry into S phase. Cell 12: 311-317, 1977.
80. Norbury C and Nurse P: Animal cell cycles and their control. Annu Rev Biochem 61: 441-470, 1992.
81. Jefferies HBJ and Thomas G: Ribosomal protein S6 phosphorylation and signal transduction. In: Translational Control. Hershey JWB, Mathews MB and Sonenberg N (eds). Cold Spring Harbor Press, New York, pp389-409, 1996.
82. Proud CG: p70 S6 kinase: an enigma with variations. Trends Biochem Sci 21: 181-185, 1996.
83. Brown EJ and Schreiber SL: A signaling pathway to translational control. Cell 86: 517-520, 1996.
84. Chou MM and Blenis J: The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol 7: 806-814, 1995.
85. S6K. FEBS Lett 410: 78-82, 1997.
86. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC Jr and Sonenberg N: Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371: 762-767, 1994.
87. Riabowol KT, Vosatka RJ, Ziff EB, Lamb NJ and Feramisco JR: Microinjcction of fos-specific antibodies blocks DNA synthesis in fibroblast cells. Mol Cell Biol 8: 1670-1676, 1988.
88. Holt JT, Gopal TV, Moulton AD and Nienhuis AW: Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc Natl Acad Sci USA 83: 4794-4798, 1986.
89. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483-16486, 1995.
90. Schilling K, Luk D, Morgan JI and Curran T: Regulation of a fos-lacZ fusion gene: a paradigm for quantitative analysis of stimulus-transcription coupling. Proc Natl Acad Sci USA 88: 5665-5669, 1991.
91. Sasakawa N, Sharif M and Hanley MR: Attenu̇ation of agonist-induced desensitization of the rat substance P receptor by progressive truncation of the C-terminus. FEBS Lett 347: 181-184, 1994.
92. Sethi T, Langdon S, Smyth J and Rozengurt E: Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 52: 2737s-2742s, 1992.
93. Woll PJ and Rozengurt E: [D-Argl,D-Phe5,D-Trp7,9,Leu11]-substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA 85: 1859-1863, 1988.
94. Reeve JG and Blechen NM: [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun 199: 1313-1319, 1994.
95. Snider RM, Constantine JW, Lowe JAD, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, et al: A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251: 435-437, 1991.
96. Su B and Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402-411, 1996.
97. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
98. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994.
99. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
100. Hunter T: Oncoprotein networks. Cell 88: 333-346, 1997.
101. Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689, 1995.
102. Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.
103. Pang L, Sawada T, Decker SJ and Saltiel AR: Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270: 13585-13588, 1995.
104. Begemann M, Kashimawo SA, Choi YA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, Heitjan DF, Schiff PB, Bruce JN and Weinstein B: Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res 2: 1017-1030, 1996.
105. Baltuch GH, Couldwell WT, Villemure JG and Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993.
106. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK and Houghton PJ: Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54: 903-907, 1994.